Compare Biogen Inc (BIIB) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Eni SpA — how do they compare? Biogen Inc trades at $205.34 (market cap $30.60B), while Eni SpA trades at $55.49 (market cap $78.80B). The key difference: Eni SpA is far larger — about 2.6× Biogen Inc's market cap, and Eni SpA pays a 4.45% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | E | |
|---|---|---|
Market Cap | $30.60B | $78.80B |
Sector | Health | Energy |
52-Week High | $216.63 | $57.61 |
52-Week Low | $128.00 | $34.03 |
Enterprise Value | $37.67B | $104.11B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
Eni (E) trades at $53.61, down 1.22% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent Q2 2026 earnings missed estimates despite 21.5% revenue growth, while the company increased its share buyback program. Valuation ratios appear attractive with a P/E of 12.08 and P/S of 0.79. Cash flow from operations remains strong at $13.33 billion for 2025, supporting dividend payments and strategic investments.
The outlook for Eni is cautiously optimistic, driven by production growth and strategic partnerships, but faces risks from commodity price volatility and geopolitical factors. Analyst consensus is mixed with 34.62% buy ratings, highlighting potential upside if operational execution improves and energy markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
